Tyra Biosciences' (TYRA) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Tyra Biosciences (NASDAQ:TYRA - Free Report) in a research note released on Tuesday,Benzinga reports. They currently have a $30.00 price objective on the stock.

Several other brokerages also recently commented on TYRA. Piper Sandler started coverage on shares of Tyra Biosciences in a report on Wednesday, May 21st. They issued an "overweight" rating and a $33.00 target price on the stock. Wedbush restated an "outperform" rating and issued a $30.00 price objective on shares of Tyra Biosciences in a research note on Friday, March 28th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $30.83.

Tyra Biosciences Price Performance

Tyra Biosciences stock traded down $0.06 during trading hours on Tuesday, hitting $10.00. The company had a trading volume of 209,584 shares, compared to its average volume of 286,105. Tyra Biosciences has a fifty-two week low of $6.42 and a fifty-two week high of $29.60. The firm has a market capitalization of $530.63 million, a P/E ratio of -6.13 and a beta of 1.07. The firm's fifty day moving average is $9.86 and its 200-day moving average is $11.38.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.47) EPS for the quarter, topping analysts' consensus estimates of ($0.49) by $0.02. Analysts anticipate that Tyra Biosciences will post -1.57 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Gilla Kaplan sold 9,568 shares of Tyra Biosciences stock in a transaction that occurred on Wednesday, June 18th. The shares were sold at an average price of $9.78, for a total value of $93,575.04. Following the completion of the transaction, the director owned 28,231 shares in the company, valued at approximately $276,099.18. The trade was a 25.31% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders have sold 61,392 shares of company stock worth $628,358 over the last quarter. 15.20% of the stock is currently owned by corporate insiders.

Institutional Trading of Tyra Biosciences

Several large investors have recently made changes to their positions in TYRA. RA Capital Management L.P. raised its position in Tyra Biosciences by 2.1% in the 4th quarter. RA Capital Management L.P. now owns 10,637,290 shares of the company's stock worth $147,858,000 after purchasing an additional 220,681 shares during the last quarter. Vestal Point Capital LP raised its stake in Tyra Biosciences by 190.9% during the 1st quarter. Vestal Point Capital LP now owns 2,879,829 shares of the company's stock worth $26,782,000 after buying an additional 1,889,829 shares during the period. Boxer Capital Management LLC bought a new position in shares of Tyra Biosciences during the 4th quarter valued at about $28,185,000. Janus Henderson Group PLC boosted its holdings in shares of Tyra Biosciences by 63.6% in the fourth quarter. Janus Henderson Group PLC now owns 1,746,320 shares of the company's stock valued at $24,291,000 after buying an additional 679,124 shares during the period. Finally, Orbimed Advisors LLC boosted its stake in Tyra Biosciences by 91.3% in the 4th quarter. Orbimed Advisors LLC now owns 1,470,086 shares of the company's stock worth $20,434,000 after purchasing an additional 701,448 shares during the period. Institutional investors own 84.14% of the company's stock.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.